• 2616 Citations
  • 27 h-Index
20062019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Kyung-Hun Lee is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 49 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2006 2019

  • 2616 Citations
  • 27 h-Index
  • 133 Article
  • 8 Review article
  • 1 Comment/debate

Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients

Kim, J. Y., Lee, E., Park, K., Jung, H. H., Park, W. Y., Lee, K-H., Sohn, J., Lee, K. S., Jung, K. H., Kim, J. H., Lee, K. H., Im, S-A. & Park, Y. H., 15 Sep 2019, In : International Journal of Cancer. 145, 6, p. 1669-1678 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Phase II Clinical Trials
Biomarkers
Breast Neoplasms
Nucleotides
Disease-Free Survival
1 Citation (Scopus)

Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients

Kim, J. Y., Lee, D. W., Lee, K-H., Min, A., Ryu, H. S., Lee, H-B., Moon, H. G., Kim, T-Y., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D., Im, S-A. & Kim, S., 30 Jul 2019, In : Breast Cancer Research and Treatment. 176, 2, p. 453-460 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Body Mass Index
Hormones
Breast Neoplasms
Thinness
Neoplasms

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Kim, J. Y., Park, S., Im, S-A., Kim, S. B., Sohn, J., Lee, K. S., Chae, Y. S., Lee, K. H., Kim, J. H., Im, Y. H., Kim, T-Y., Lee, K-H., Ahn, J. H., Kim, G. M., Park, I. H., Lee, S. J., Han, H. S., Kim, S. H., Jung, K. H. & Park, Y. H., 28 May 2019, In : Cancer Communications. 39, 1, 29.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
eribulin
gemcitabine
Paclitaxel
Multicenter Studies
Quality of Life

Prognostic effects of abnormal DNA damage response protein expression in breast cancer

Suh, K. J., Ryu, H. S., Lee, K-H., Kim, H., Min, A., Kim, T-Y., Yang, Y., Lee, H-B., Moon, H. G., Han, S-W., Oh, D-Y., Han, W., Park, I., Noh, D. & Im, S-A., 15 May 2019, In : Breast Cancer Research and Treatment. 175, 1, p. 117-127 11 p.

Research output: Contribution to journalArticleResearchpeer-review

DNA Damage
Breast Neoplasms
Proteins
Triple Negative Breast Neoplasms
Disease-Free Survival
2 Citations (Scopus)

Major clinical research advances in gynecologic cancer in 2018

Kim, M., Suh, D. H., Lee, K-H., Eom, K. Y., Toftdahl, N. G., Mirza, M. R. & Kim, J-W., 1 Mar 2019, In : Journal of Gynecologic Oncology. 30, 2, e18.

Research output: Contribution to journalReview articleResearchpeer-review

Open Access
Uterine Cervical Neoplasms
Research
Neoplasms
Drug Therapy
Survival